Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib PK and Safety in Chinese Patients with Advanced Solid Tumors
NCT04635631Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in solid tumor (advanced stage), sponsored by Pfizer. Primary endpoints: Maximum Observed Concentration (Cmax) of Talazoparib Following Single Oral Dose, Time to Cmax (Tmax) of Talazoparib Following Single Oral Dose and 13 more. Started Nov 2020; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04635631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635631.